A5100360443- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Multiple Myeloma Research and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Cutaneous lymphoproliferative disorders research
- Chromosomal and Genetic Variations
- CRISPR and Genetic Engineering
- Plant Molecular Biology Research
- Nanowire Synthesis and Applications
- Immune Cell Function and Interaction
- Advancements in Semiconductor Devices and Circuit Design
- Integrated Circuits and Semiconductor Failure Analysis
- Insect Resistance and Genetics
- Monoclonal and Polyclonal Antibodies Research
- Genomics and Chromatin Dynamics
- Genetic factors in colorectal cancer
- Pancreatic function and diabetes
- Liver Disease Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Silicon Carbide Semiconductor Technologies
- Modular Robots and Swarm Intelligence
- RNA Interference and Gene Delivery
- Plant nutrient uptake and metabolism
- Teleoperation and Haptic Systems
Huazhong University of Science and Technology
2022-2025
Xuzhou Medical College
2021-2024
Tongji Hospital
2022-2024
Cancer Institute (WIA)
2023
First Affiliated Hospital Zhejiang University
2023
Zhejiang University
2023
Zhongda Hospital Southeast University
2022-2023
Institute of Zoology
2023
Chinese Academy of Sciences
2023
WuXi AppTec (China)
2022
Background & AimsHepatocellular carcinoma (HCC) is often associated with hepatitis B virus (HBV) infection. Cells of most HBV-related HCCs contain HBV-DNA fragments that do not encode entire HBV antigens. We investigated whether these integrated epitopes are recognized by T cells and their presence in can be used to select HBV-specific T-cell receptors (TCRs) for immunotherapy.MethodsHCC negative antigens, based on immunohistochemistry, were analyzed the messenger RNAs (mRNAs) real-time...
Chimeric antigen receptor T-cell (CAR-T) is particularly prominent in hematological but not solid tumors, mainly based on the complex tumor immune microenvironment. Oncolytic virus (OVs) an emerging adjuvant therapy method. OVs may prime lesions to induce anti-tumor response, thereby enhancing CAR-T cells functionality and possibly increasing response rates. Here, we combined targeting carbonic anhydrase 9 (CA9) oncolytic adenovirus (OAV) carrying chemokine (C-C motif) ligand 5 (CCL5),...
8005 Background: GC012F is a chimeric antigen receptor (CAR)-T cell therapy with B maturation (BCMA) and CD19 dual-target developed on the novel FasT CAR-T platform enabling 22-36 h manufacturing. Our previous results were presented at ASCO EHA 2022 for 29 pts (NCT04236011; NCT04182581), which demonstrated treatment led to deep durable response in RRMM pts. Furthermore, initial showed that considerable efficacy safety high-risk transplant-eligible newly diagnosed MM (Blood 2022; 140...
Glioblastoma survival remains unchanged despite continuing therapeutic innovation. Herein, we aim to (i) develop chimeric antigen receptor (CAR) T cells with a specificity unique antigen, carbonic anhydrase IX (CAIX), which is expressed in the hypoxic microenvironment characteristic of glioblastoma, and (ii) demonstrate its efficacy limited off-target effects.First demonstrated expression CAIX patient-derived glioblastoma samples available databases. CAR were generated against was assessed 4...
Background Solid tumors pose unique roadblocks to treatment with chimeric antigen receptor (CAR) T cells, including limited T-cell persistence, inefficient tumor infiltration, and an immunosuppressive microenvironment. To date, attempts overcome these have been unsatisfactory. Herein, we reported a strategy of combining Runx3 (encoding RUNX family transcription factor 3)-overexpression ex vivo protein kinase B (AKT) inhibition generate CAR-T cells both central memory tissue-resident...
Abstract The efficacy of chimeric antigen receptor T (CAR-T) cells for solid tumors remains unsatisfactory due to the limited tumor infiltration and immunosuppressive microenvironment. To overcome these limitations, genetically engineered recombinant oncolytic adenoviruses (OAVs) that conditionally replicate in were developed modify microenvironment (TME) facilitate CAR-T-mediated eradication. Here present study, a novel OAV carrying CCL5, IL12, IFN-γ controlled by Ki67 promoter was...
Since the Coronavirus Disease 2019 (COVID-19) outbreak, unconventional cell line development (CLD) strategies have been taken to enable of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies at expedited speed. We previously reported a novel chemistry, manufacturing, and control (CMC) workflow demonstrated much-shortened timeline 3-6 months from DNA investigational new drug (IND) application. Hereafter, we incorporated this CMC strategy for many...
Patients with Burkitt lymphoma who are refractory to initial therapy or relapse after undergoing intensive chemotherapy and autologous stem cell transplantation (ASCT) usually have a poor prognosis. While there has been considerable progress in the use of chimeric antigen receptor-modified (CAR) T immunotherapy for treatment relapsed (r/r) malignancies, explicit data on adult patients r/r limited. We conducted two single-arm clinical trials evaluate efficacy toxicity CD19/CD22 CAR both alone...
Formation of nucleosomes along eukaryotic DNA has an impact on transcription. Major transcriptional changes occur in response to low external phosphate (Pi) plants, but the involvement chromatin-level mechanisms Pi starvation responses have not been investigated.
Burkitt’s lymphoma (BL) with TP53 mutation often has poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR)-T cell therapy may be a new paradigm for treating refractory/relapsed (r/r) BL, but its therapeutic effects remain inconclusive. Here, we report patient r/r BL who failed to achieve complete remission (CR) and progressed rapidly multiple protocol chemotherapy. The achieved CR CAR19 CAR22 T-cell cocktail obtained long-term disease-free survival...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: GC012F is a B cell maturation antigen (BCMA) CD19 dual-targeting chimeric receptor (CAR)-T developed on the novel FasTCAR-T platform enabling 22-36 h manufacturing. Our previous results presented at ASCO EHA 2022 for 29 pts (NCT04236011; NCT04182581), demonstrated that treatment led to deep durable response in RRMM pts. Furthermore, initial showed considerable efficacy safety of newly diagnosed high-risk...
The technology of adoptive transfer T-cell receptor (TCR) engineered T cells is wildly investigated as it has the potential to treat solid cancers. However, therapeutic application TCR-T hampered by poor quality derived mainly from patients' peripheral blood, well heterogeneous TCRs caused mismatch between transgenic and endogenous TCRs. To improve homogeneity, antigen-specificity reduce possible autoreactivity, here we developed a technique generate antigen-specific Rag2 gene-deleted...